Community curated by people like you

Trenton stories

Oct 26, 2026

Eli Lilly wins court ruling allowing weight-loss drug ads against Novo Nordisk

A US court denied Novo Nordisk's request to temporarily block Eli Lilly from using advertisements claiming its obesity drugs are more powerful, a setback for Novo as it battles to regain market share.

Oct 26, 2026·2 sources

00

Top claims

▪Eli Lilly's lawyers argued in court filings that Eli Lilly's advertisements were factual and truthful because Eli Lilly ran head-to-head clinical trials that Novo Nordisk failed to match
▪Novo Nordisk Chief Executive Officer Mike Doustdar made litigation against competitors part of his strategy to claw back market share
▪Eli Lilly's advertisements state that Zepbound users lost an average of 50 pounds while Wegovy users lost 33 pounds, based on a 2025 head-to-head clinical study

Topics

Weight loss drugs Zepbound Market competition Novo Nordisk Pharmaceutical marketing Eli Lilly Obesity treatment GLP-1

Related entities

Ozempic United States